Clinical Trial Update: Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) [Phase 1]

View source ↗

Summary

This Phase 1 trial of MDX-1203 in patients with clear cell renal cell carcinoma and relapsed/refractory B-cell non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Renal Cell Carcinoma

Drugs mentioned

• MDX-1203

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Renal Cell Carcinoma, Non-hodgkin's Lymphoma | Phase 1 | Status: COMPLETED